Gary Jennings

JADO Technologies GmbH develops novel small molecule drugs. It offers drugs based on an unrivalled insight into cell membrane biology and the role of specific cellular domains, including lipid rafts. The firm's technology provides an insight into diverse pathological mechanisms and drives the design of innovative drugs with new modes of action. The company was founded by Teymuras Kurzchalia, Hans-Joachim Knölker, Gary Jennings, Kai Simons and Marino Zerial in 2001 and is headquartered in Dresden, Germany.

Part of Baxter International, Inc., Ribonetics GmbH is a German company that develops RILON technology, a therapeutic treatment. The company is located in Germany. Ribonetics was acquired by Nexell Therapeutics, Inc. on May 23, 1996 for $1.50 million.

DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany.

Part of Evotec SE, HepaVec AG is a German pharmaceutical company that develops pharmaceutical products. The company is based in Berlin, Germany. HepaVec was acquired by DeveloGen AG on May 01, 2000 for $46.57 million.